UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2025 Delaware 11-3146460 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 14 Plaza Drive, Latham, New York 12110 (Address of principal executive offices and zip code) OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

Key Takeaways ANGO posted Q4 FY25 revenues of $80.2 million, up 12.9% and ahead of the consensus mark by 7.5%. Adjusted Q4 loss per share of 3 cents narrowed from 6 cents and beat the consensus mark of 13 cents. Gross margin fell 161 bps to 52.7% despite 9.4% growth in pro forma gross profit.AngioDynamics, Inc. (ANGO) reported an adjusted loss per share of 3 cents for fourth-quarter fiscal 2025, narrower than the year-ago quarter’s adjusted loss per share of 6 cents and the Zacks Consensus Estimate of a l ...

AngioDynamics' big Q4 earnings beat wasn't as impressive as it first seemed.Tuesday started off well for AngioDynamics (ANGO -10.18%), maker of such medical devices as the NanoKnife tool for "electrocuting" cancer, as well as multiple devices for treating peripheral vascular disease. In the morning, AngioDynamics reported stronger-than-expected Q4 2025 sales and earnings, with sales of $80.2 million and an adjusted loss of $0.03 per share (instead of the $0.12-per-share forecast).By the end of the day, howe ...

AngioDynamics Inc. (NASDAQ: ANGO) on Tuesday posted a fourth-quarter 2025 adjusted loss of 3 cents per share, compared to the consensus for a per-share loss of 12 cents.Vascular system-focused medical device maker reported sales of $80.2 million, up 12.7% year over year, beating the consensus of $74.26 million.The report also revealed:Med Tech net sales were $35.8 million, a 22% increase from $29.3 million in the prior-year period.Growth was driven by Auryon sales during the quarter of $15.6 million, which ...

Image source: The Motley Fool. Tuesday, July 15, 2025 at 8:00 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer — Jim Clemmer Executive Vice President and Chief Financial Officer — Steve Trowbridge Need a quote from one of our analysts? Email [email protected] RISKS Tariff Expenses: Steve Trowbridge reported $1.6 million in tariff expenses impacting results for Q4 FY2025, with an estimated full-year tariff impact of $4-$6 million for FY2026. Negative Year-over-Year NanoKnife Revenue: Steve Tro ...

Financial Data and Key Metrics Changes - Total revenue for the fourth quarter was $80.2 million, representing a year-over-year growth of over 12% [5][23] - MedTech revenue was $35.8 million, a 22% increase, while Med Device revenue was $44.4 million, an increase of 6.2% [23] - For the full fiscal year, total revenue increased by 8.1% to $292.7 million, primarily driven by growth in the MedTech segment [34][35] - Gross margin for the fourth quarter was 52.7%, with MedTech gross margin at 59% and Med Device gross margin at 47.6% [30][36] Business Line Data and Key Metrics Changes - AURYON platform generated $15.6 million in revenue, growing 19.7% year-over-year [23] - Mechanical thrombectomy revenue, including AngioVac and AlphaVac, increased by 44.7% year-over-year, with AngioVac revenue at $8.2 million (39.5% increase) and AlphaVac revenue at $3.1 million (60.8% increase) [24] - NanoKnife revenue totaled $7.2 million, a decrease of 2.5%, attributed to lower capital sales, while disposable sales grew by 5.5% [25] Market Data and Key Metrics Changes - Hospital customers represented approximately 36% of total AURYON revenue, up from 28% at the beginning of fiscal 2025 [7] - In Europe, over $1 million in revenue was generated from AURYON, indicating successful market entry following CE Mark approval [8] Company Strategy and Development Direction - The company is focused on a long-term strategic transformation to simplify its business and enter high-growth, high-margin MedTech markets [5][20] - Continued investment in R&D is planned, targeting approximately 10% of sales to support long-term growth in the MedTech segment [31] - The company aims to drive adoption and market share gains across its MedTech platforms while maintaining operational discipline [41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate tariff impacts and maintain profitability, expecting to be cash flow positive in fiscal 2026 [20][39] - The company anticipates net sales for fiscal 2026 to be in the range of $305 million to $310 million, representing growth of 46% over fiscal 2025 [38] Other Important Information - The company achieved significant regulatory approvals and reimbursement wins, which are expected to drive future growth [5][15] - The company incurred $1.6 million in tariff expenses during the fourth quarter, impacting gross margins [28] Q&A Session Summary Question: Details on the blood return product for the VTE business - Management confirmed that the blood return product is designed as an ancillary add-on and is undergoing the 510(k) regulatory process, with confidence in its market potential [46][50] Question: Expectations for NanoKnife growth with upcoming reimbursement - Management indicated that reimbursement starting in January 2026 is expected to drive growth, although immediate acceleration may not be seen [52][56] Question: Major product growth expectations for FY 2026 - Management expects AURYON to grow in the mid-teens, while mechanical thrombectomy products are anticipated to show the strongest growth [60][63] Question: Impact of tariffs on gross margin and outsourcing benefits - Management acknowledged the complexity of tariff impacts and indicated that benefits from the manufacturing transfer plan will be seen in FY 2026 [64][66] Question: Plans for acquiring new MedTech products or divesting existing ones - Management expressed satisfaction with the current portfolio and indicated no immediate plans for acquisitions or divestitures, focusing instead on maximizing existing assets [70][74]

AngioDynamics Fourth Quarter and Full Year Earnings Presentation July 15, 2025 Forward-Looking Statements Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, ...

Exhibit 99.1 AngioDynamics Reports Strong Fiscal Year 2025 Fourth Quarter and Full Year Financial Results; Continued Execution Driving Accelerated, Profitable Growth Med Tech franchise delivers third consecutive quarter of over 20% revenue growth Reported strong adjusted EBITDA in the fourth quarter resulting in positive adjusted EBITDA for full fiscal year 2025 Drove $16.2 million of free cash flow in the quarter as a result of strong topline growth and operational ef iciency ef orts LATHAM, N.Y.--(BUSINES ...

For Immediate ReleaseChicago, IL – June 9, 2025 – Today, Zacks Equity Research discusses Penumbra (PEN) , Integer Holdings (ITGR) and AngioDynamics (ANGO) .Industry: Medical InstrumentsLink: https://www.zacks.com/commentary/2487141/3-medical-instruments-stocks-winning-big-with-genai-amid-global-gloomOver the past year, advancements in artificial intelligence (AI) and predictive analytics have rapidly revolutionized the Medical Instruments industry, driving innovation in diagnostics, patient monitoring and p ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for moment ...